Merrion Pharmaceuticals, Inc. to Cut 20 Dublin Jobs
9/2/2011 8:07:24 AM
More...
|
Merrion Pharmaceuticals, Inc. and Novo Nordisk A/S (NVO) Sign EUR 1.5M Deal for Oral Formulation Technology
12/22/2010 8:10:16 AM
More...
|
Merrion Pharmaceuticals, Inc. Signs Feasibility and Option Agreement for 3 Drugs With International 'Top Ten' Pharmaceutical Company
12/6/2010 11:07:49 AM
More...
|
Merrion Pharmaceuticals, Inc. Announces Commencement of Feasibility and Option Agreement With Rebel Pharmaceuticals
11/23/2010 11:20:48 AM
More...
|
Merrion Pharmaceuticals, Inc. Finalises Its Phase III Development Program for Orazol(TM) in the USA
11/16/2010 9:40:59 AM
More...
|
Merrion Pharmaceuticals, Inc. is Issued a Key U.S. Patent for Orazol(TM), Their Lead Product to Treat Bone Metastases Associated With Prostate, Breast and Other Cancers
5/7/2010 9:52:26 AM
More...
|
Merrion Pharmaceuticals, Inc. is Issued a Key United States Patent
3/2/2010 8:33:46 AM
More...
|
Novo Nordisk A/S (NVO) Starts Phase 1 Trial With Oral Insulin Analogue -- Merrion Pharmaceuticals, Inc. Earns USD 2 Million Milestone Payment
12/7/2009 8:52:18 AM
More...
|
Merrion Pharmaceuticals, Inc. Announces Preliminary Results On Phase II Orazol(tm) Study
5/15/2009 9:45:09 AM
More...
|
Merrion Pharmaceuticals, Inc. Announces License Agreement With Novo Nordisk A/S (NVO) to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion
1/16/2009 7:05:03 AM
More...
|
|